Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2022Future OncologyOpen Access

Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial

View Full Paper
Ask AI
Bookmark
Share

Authors

Jorge E. Cortés
Jorge E. CortésAugusta University Health
Andreas Hochhaus
Andreas HochhausSouth Australia PathologyNTNaoto TakahashiAkita University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cortes et al. (2022) studied this question.

synapsesocial.com/papers/6a851689021134ddee54deadhttps://doi.org/10.2217/fon-2022-0923
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A graphical approach to sequentially rejective multiple test procedures2008 · 420 citations
  2. 2Epidemiologic Signatures in Cancer2019 · 210 citations
  3. 3Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial2016 · 859 citations
  4. 4Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia2006 · 3,515 citations
  5. 5A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs2021 · 346 citations